The Pharmaceutical Market: Lithuania


We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012 , with the market expected to increase by a local currency margin of 2.5% year-on-year (y-o-y) to reach LTL1.6 8 bn (US$6 18 mn) in 2012 at consumer prices. However, in US dollar terms, the market \' s value will shrink by 6.3%, in dicating the challenges facing companies operating in the market .

Headline Expenditure Projections

  • Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5% in local currency terms and -6.3% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data.
  • Healthcare: LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up from Q4 12 on account of new macroeconomic data.
  • Medical devices: LTL679mn (US$273mn) in 2011 to LTL749mn (US$276mn) in 2012; +10.3% in local currency terms and +0.8% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data.


Risk/Reward Rating

In our Q1 13 Pharmaceuticals Risk/Reward Rating (RRR) matrix, Lithuania is 15th, out of the 20 markets surveyed in Emerging Europe, below its Baltic peers. Although Lithuania boasts a largely risk-free operating environment, its muted rewards prospects will continue to impact its standing in the regional matrix. Globally, Lithuania ranks 60th out of 95 markets surveyed.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

To Download Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=193652

Table of Contents

Executive Summary7
SWOT Analysis9
Lithuania Pharmaceuticals And Healthcare Industry SWOT9
Lithuania Political SWOT10
Lithuania Economic SWOT10
Lithuania Business Environment SWOT11
Pharmaceuticals Risk/Reward Ratings12
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q21312
Rewards13
Risks13
Lithuania - Market Summary15
Regulatory Regime17
Regional Harmonisation18
Pharmaceutical Advertising19
Intellectual Property Developments20
Pricing Regime21
Pricing Developments22


For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074

Comments

Popular posts from this blog

Global Organic Drinks Industrial Trend and Market Demand 2016-2020

Global Night Vision Devices Industrial Trend and Market Demand 2016-2020

Global Handling and Lifting Equipment Industrial Trend and Market Demand 2016-2020